TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition.

Specific chromosomal translocations encoding chimeric transcription factors are considered to play crucial oncogenic roles in a variety of human cancers but the fusion proteins themselves seldom represent suitable therapeutic targets. Oncogenic TFE3 fusion proteins define a subset of pediatric renal adenocarcinomas and one fusion (ASPL-TFE3) is also characteristic of alveolar soft part sarcoma (ASPS). By expression profiling, we identified the MET receptor tyrosine kinase gene as significantly overexpressed in ASPS relative to four other types of primitive sarcomas. We therefore examined MET as a direct transcriptional target of ASPL-TFE3. ASPL-TFE3 binds to the MET promoter and strongly activates it. Likewise, PSF-TFE3 and NONO-TFE3 also bind this promoter. Induction of MET by ASPL-TFE3 results in strong MET autophosphorylation and activation of downstream signaling in the presence of hepatocyte growth factor (HGF). In cancer cell lines containing endogenous TFE3 fusion proteins, inhibiting MET by RNA interference or by the inhibitor PHA665752 abolishes HGF-dependent MET activation, causing decreased cell growth and loss of HGF-dependent phenotypes. MET is thus a potential therapeutic target in these cancers. Aberrant transcriptional up-regulation of MET by oncogenic TFE3 fusion proteins represents another mechanism by which certain cancers become dependent on MET signaling. The identification of kinase signaling pathways transcriptionally up-regulated by oncogenic fusion proteins may reveal more accessible therapeutic targets in this class of human cancers.

[1]  M. Ladanyi,et al.  Xp11 Translocation Renal Cell Carcinoma in Adults: Expanded Clinical, Pathologic, and Genetic Spectrum , 2007, The American journal of surgical pathology.

[2]  H. Kanetake,et al.  Presence of Phosphorylated Hepatocyte Growth Factor Receptor/c-Met Is Associated with Tumor Progression and Survival in Patients with Conventional Renal Cell Carcinoma , 2006, Clinical Cancer Research.

[3]  R. Bernards,et al.  A Functional Genetic Screen Identifies TFE3 as a Gene That Confers Resistance to the Anti-proliferative Effects of the Retinoblastoma Protein and Transforming Growth Factor-β* , 2006, Journal of Biological Chemistry.

[4]  C. Scuoppo,et al.  Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma. , 2006, Cancer research.

[5]  D. Fisher,et al.  c-Met Expression Is Regulated by Mitf in the Melanocyte Lineage* , 2006, Journal of Biological Chemistry.

[6]  F. Meyskens,et al.  Microphthalmic-associated transcription factor integrates melanocyte biology and melanoma progression. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  Gayatry Mohapatra,et al.  Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752 , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[8]  David E Fisher,et al.  Inhibition of the Met Receptor in Mesothelioma , 2005, Clinical Cancer Research.

[9]  T. Golub,et al.  Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma , 2005, Nature.

[10]  Sandra Kleiner,et al.  Activation of the c‐Met receptor complex in fibroblasts drives invasive cell behavior by signaling through transcription factor STAT3 , 2005, Journal of cellular biochemistry.

[11]  M. Ladanyi,et al.  Translocation carcinomas of the kidney. , 2005, Clinics in laboratory medicine.

[12]  J. Christensen,et al.  A Selective Small Molecule c-MET Inhibitor, PHA665752, Cooperates with Rapamycin , 2005, Clinical Cancer Research.

[13]  T. Golub,et al.  Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. , 2004, Cancer cell.

[14]  Y. Kaneko,et al.  Establishment and characterization of a renal cell carcinoma cell line (FU-UR-1) with the reciprocal ASPL-TFE3 fusion transcript. , 2004, Oncology reports.

[15]  W. Birchmeier,et al.  Met, metastasis, motility and more , 2003, Nature Reviews Molecular Cell Biology.

[16]  J. Christensen,et al.  A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. , 2003, Cancer research.

[17]  H. Lodish,et al.  Functional cloning of TUG as a regulator of GLUT4 glucose transporter trafficking , 2003, Nature.

[18]  J. Downing,et al.  Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. , 2003, Blood.

[19]  S. Ramaswamy,et al.  MLANA/MART1 and SILV/PMEL17/GP100 are transcriptionally regulated by MITF in melanocytes and melanoma. , 2003, The American journal of pathology.

[20]  M. Ladanyi,et al.  Cloning of an Alpha-TFEB fusion in renal tumors harboring the t(6;11)(p21;q13) chromosome translocation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[21]  T. Hunter,et al.  The Protein Kinase Complement of the Human Genome , 2002, Science.

[22]  M. Ladanyi,et al.  PRCC-TFE3 Renal Carcinomas: Morphologic, Immunohistochemical, Ultrastructural, and Molecular Analysis of an Entity Associated With the t(X;1)(p11.2;q21) , 2002, The American journal of surgical pathology.

[23]  M. Kohno,et al.  Prolonged Nuclear Retention of Activated Extracellular Signal-regulated Kinase 1/2 Is Required for Hepatocyte Growth Factor-induced Cell Motility* , 2002, The Journal of Biological Chemistry.

[24]  R. Salgia,et al.  Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. , 2002, Cytokine & growth factor reviews.

[25]  R. Jove,et al.  Requirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesis , 2002, Oncogene.

[26]  M. Ladanyi,et al.  Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents. , 2001, The American journal of pathology.

[27]  L. Cantley,et al.  Differential MAPK Pathways Utilized for HGF- and EGF-dependent Renal Epithelial Morphogenesis* , 2001, The Journal of Biological Chemistry.

[28]  C. Cooper,et al.  PRCC, the commonest TFE3 fusion partner in papillary renal carcinoma is associated with pre-mRNA splicing factors , 2001, Oncogene.

[29]  Alfons Meindl,et al.  The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25 , 2001, Oncogene.

[30]  D. Robinson,et al.  The protein tyrosine kinase family of the human genome , 2000, Oncogene.

[31]  K. Furge,et al.  Met receptor tyrosine kinase: enhanced signaling through adapter proteins , 2000, Oncogene.

[32]  A. G. Kessel,et al.  Nuclear localization and transactivating capacities of the papillary renal cell carcinoma-associated TFE3 and PRCC (fusion) proteins , 2000, Oncogene.

[33]  R. Davis,et al.  Up-regulation of MET but not neural cell adhesion molecule expression by the PAX3-FKHR fusion protein in alveolar rhabdomyosarcoma. , 1998, Cancer research.

[34]  J. Downward,et al.  Phosphoinositide 3-Kinase Induces Scattering and Tubulogenesis in Epithelial Cells through a Novel Pathway* , 1998, The Journal of Biological Chemistry.

[35]  E. Price,et al.  MAP kinase links the transcription factor Microphthalmia to c-Kit signalling in melanocytes , 1998, Nature.

[36]  Damian Smedley,et al.  Fusion of splicing factor genes PSF and NonO (p54nrb) to the TFE3 gene in papillary renal cell carcinoma , 1997, Oncogene.

[37]  S. Scherer,et al.  Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas , 1997, Nature Genetics.

[38]  A. G. Kessel,et al.  Fusion of the transcription factor TFE3 gene to a novel gene, PRCC, in t(X;1)(p11;q21)-positive papillary renal cell carcinomas. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[39]  W. Birchmeier,et al.  Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis , 1996, Nature.

[40]  S Gill,et al.  The t(X;1)(p11.2;q21.2) translocation in papillary renal cell carcinoma fuses a novel gene PRCC to the TFE3 transcription factor gene. , 1996, Human molecular genetics.

[41]  C. Cooper,et al.  Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma , 1994, Nature Genetics.

[42]  T. Matsuno,et al.  Morphological and Cytogenetic Studies of a Human Synovial Sarcoma Xenotransplanted into Nude Mice , 1990, Acta pathologica japonica.

[43]  J. Guan,et al.  Wound-healing assay. , 2005, Methods in molecular biology.

[44]  G. Woude,et al.  HGF/SF-Met signaling in tumor progression , 2005, Cell Research.

[45]  M. Urioste,et al.  Short communication Characterization of the A673 cell line (Ewing tumor) by molecular cytogenetic techniques , 2003 .

[46]  M. Furihata,et al.  Establishment and characterization of a new human synovial sarcoma cell line, HS-SY-II. , 1992, Laboratory investigation; a journal of technical methods and pathology.